Abstract:The COVID-19 disease is caused by a new strain of the coronavirus family (SARS-CoV-2), and it has affected at present millions of people all over the world. The indispensable role of the main protease (Mpro) in viral replication and gene expression makes this enzyme an attractive drug target. Therefore, inhibition of SARS-CoV-2 Mpro as a proposition to halt virus ingression is being pursued by scientists globally. Here we carried out a study with two objectives: the first being to perform comparative protein sequence and 3D structural analysis to understand the effect of 12 point mutations on the active site. Among these, two mutations, viz., Ser46 and Phe134, were found to cause a significant change at the active sites of SARS-CoV-2. The Ser46 mutation present at the entrance of the S5 subpocket of SARS-CoV-2 increases the contribution of other two hydrophilic residues, while the Phe134 mutation, present in the catalytic cysteine loop, can cause an increase in catalytic efficiency of Mpro by facilitating fast proton transfer from the Cys145 to His41 residue. It was observed that active site remained conserved among Mpro of both SARS-CoVs, except at the entrance of the S5 subpocket, suggesting sustenance of substrate specificity. The second objective was to screen the inhibitory effects of three different data sets (natural products, coronaviruses main protease inhibitors, and FDA-approved drugs) using a structure-based virtual screening approach. A total of 73 hits had a combo score >2.0. Eight different structural scaffold classes were identified, such as one/two tetrahydropyran ring(s), dipeptide/tripeptide/oligopeptide, large (approximately 20 atoms) cyclic peptide, and miscellaneous. The screened hits showed key interactions with subpockets of the active site. Further, molecular dynamics studies of selected screened compounds confirmed their perfect fitting into the subpockets of the active site. This study suggests promising structures that can fit into the SARS-CoV-2 Mpro active site and also offers direction for further lead optimization and rational drug design.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jcim.0c00546?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jcim.0c00546</a>.Phylogenetic relationship of SARS-CoV-2 Mpro; superimposed cocrystallized and redocked ligand; protein thermodynamic stability information upon point mutations; list of top Mpro inhibitors with their structures, source and scaffold information; interaction fraction histogram obtained from MD simulations; protein-ligand contact timeline information; RMSF plot for protein in presence of different ligands; binding free energy plot; and analysis of impact of mutation on active site residues of Mpro (<a class="ext-link" href="/doi/suppl/10.1021/acs.jcim.0c00546/suppl_file/ci0c00546_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Improved expression and purification of highly-active 3 chymotrypsin-like protease from SARS-CoV-2

REVISITING THE SARS-COV-2 MAIN PROTEASE: A 2023 IN SILICO ODYSSEY IN SEARCH OF POTENTIAL INHIBITORS

3-chymotrypsin-like protease in SARS-CoV-2

Molecular Cloning, Expression, Purification, and Mass Spectrometric Characterization of 3C-Like Protease of SARS Coronavirus

Production of Authentic SARS-CoV M(pro) with Enhanced Activity: Application As a Novel Tag-Cleavage Endopeptidase for Protein Overproduction.

3-Chymotrypsin-like Protease (3CLpro) of SARS-CoV-2: Validation as a Molecular Target, Proposal of a Novel Catalytic Mechanism, and Inhibitors in Preclinical and Clinical Trials

The main protease 3CLpro of the SARS-CoV-2 virus: how to turn an enemy into a helper

Expression, purification, and biological activity evaluation of cathepsin L in mammalian cells

Novel Alkynylamide-Based Nonpeptidic Allosteric Inhibitors for SARS-CoV-2 3-Chymotrypsin-like Protease

pH profiles of 3-chymotrypsin-like protease (3CLpro) from SARS-CoV-2 elucidate its catalytic mechanism and a histidine residue critical for activity

Catalytic Dyad Residues His41 and Cys145 Impact the Catalytic Activity and Overall Conformational Fold of the Main SARS-CoV-2 Protease 3-Chymotrypsin-Like Protease

Comprehensive Insights into the Catalytic Mechanism of Middle East Respiratory Syndrome 3C-Like Protease and Severe Acute Respiratory Syndrome 3C-Like Protease

Bioengineered amyloid peptide for rapid screening of inhibitors against main protease of SARS-CoV-2

Biosynthesis, Purification, and Substrate Specificity of Severe Acute Respiratory Syndrome Coronavirus 3C-Like Proteinase

Rapid Peptide-Based Screening on the Substrate Specificity of Severe Acute Respiratory Syndrome (SARS) Coronavirus 3C-Like Protease by Matrix-Assisted Laser Desorption/ionization Time-of-flight Mass Spectrometry.

Characterisation of Recombinant 3CL Protease from SARS-CoV-2 Produced in E. coli BL21 (DE3) for Screening Anti-Covid Drug Candidates using Rhodamine 110-Synthetic Peptide Conjugate as A Substrate

Sensitive detection of SARS‐CoV‐2 main protease 3CLpro with an engineered ribonuclease zymogen

Optimization of quenched fluorescent peptide substrates of SARS-CoV-2 3CLpro main protease (Mpro) from proteomic identification of P6—P6' active site specificity

Orthogonal dual reporter-based gain-of-signal assay for probing SARS-CoV-2 3CL protease activity in living cells: inhibitor identification and mutation investigation

Structure-Based Virtual Screening to Discover Potential Lead Molecules for the SARS-CoV-2 Main Protease

Assay Development and Validation for Innovative Antiviral Development Targeting the N-Terminal Autoprocessing of SARS-CoV-2 Main Protease Precursors